[Controlled clinical trial of a new antibiotic "CM 9164" (Midecacin) in dental and stomatological practice].
The action of a new antibiotic identified as CM 9164 ("Midecamycin") and provisionally called "Midecacin", has been experimented on patients admitted for dental conditions. The research was carried out on an open basis and erythromycin was used as a comparison. After a short review of the chemicophysical properties and toxicological and pharmacological features of Midecamycin, the purpose, materials and methods of the research, which was done on two groups of patients, are presented. The results demonstrated the therapeutics usefulness of the new antibiotic as its activity is certainly on a par if not greater than that of erythromycin whether considered "historically" or from the viewpoint of the comparison group. The tolerance of the antibiotic was clinically better than that of the other substances. The doses used were much lower than those required with erythromycin. On the basis of these results, the use of Midecamycin is therefore recommended in the treatment of Gram-positive infections in the dental field.